Virios Therapeutics, Inc. (VIRI)
NASDAQ: VIRI · IEX Real-Time Price · USD
0.351
-0.035 (-8.96%)
At close: May 17, 2024, 3:59 PM
0.233
-0.119 (-33.78%)
After-hours: May 17, 2024, 7:59 PM EDT
Company Description
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Virios Therapeutics, Inc.
| Country | United States |
| IPO Date | Dec 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | (866) 620-8655 |
| Website | virios.com |
Stock Details
| Ticker Symbol | VIRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001818844 |
| CUSIP Number | 92829J104 |
| ISIN Number | US92829J1043 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman and Chief Executive Officer |
| Dr. William L. Pridgen M.D. | Founder and Director |
| Angela Walsh | Chief Financial Officer, SVice President of Finance, Corporate Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | 424B4 | Prospectus |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 8, 2024 | 10-K/A | [Amend] Annual report |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |